Submit Article
Back to Journal

SM Case Reports

Topical Treatment of Vaginal Melanoma in situ with Imiquimod (Aldara

[ ISSN : 2473-0688 ]

Abstract
Details

Received: 08-Nov-2017

Accepted: 11-Dec-2017

Published: 05-Dec-2017

Case Report | Volume 3 - Issue 8 | Article DOI :

Download PDF

Charles RBW¹*, Van de Vijver KK², Hermans RHM³, and Lok CAR¹

¹Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, The Netherlands

²Division of Diagnostic Oncology & Molecular Pathology, The Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, The Netherlands

³Department of Gynecologic Oncology, Catharina Hospital Eindhoven, The Netherlands

Corresponding Author:

Charles RBW, Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, The Netherlands, Tel: +597442222 (or) +5978574448; Email: rcharles@azp.sr (or) charlesregillio@yahoo.com

Keywords

Imiquimod; Melanoma; Melanoma in situ; Vaginal melanoma; Vaginal melanoma in situ

Abstract

Melanomas of the vulva and vagina comprise less than 2% of melanomas in women and the overall prognosis is poor. Imiquimod (Aldara®) cream has shown to be effective in non-gynecologic cases of melanoma in situ but is less frequently used in gynecologic cases. We report a case of vaginal melanoma in situ treated with imiquimod. The usual treatment of vaginal melanoma in situ and vaginal melanoma is surgery. There are only a few case reports in the literature that show the effect of treatment of vaginal and vulvar melanoma in situ with imiquimod.

Citation

Charles RBW, Van de Vijver KK, Hermans RHM and Lok CAR. Topical Treatment of Vaginal Melanoma in situ with Imiquimod (Aldara®). SM J Case Rep. 2017; 3(8): 1073.